Success Metrics

Active Trials

3(75%)

Phase Distribution

Ph phase_1

75%

Ph phase_2

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Recruiting3

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

recruiting375%

not_yet_recruiting125%

Recent Activity

3 active trials

Showing 4 of 4

not_yet_recruitingphase_2

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

NCT07413601

recruitingphase_1

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

NCT07256782

recruitingphase_1

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

NCT06336707

recruitingphase_1

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

NCT06332170

Clinical Trials (4)

Showing 4 of 4 trials

NCT07413601Phase 2

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

Not Yet Recruiting

NCT07256782Phase 1

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Recruiting

NCT06336707Phase 1

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Recruiting

NCT06332170Phase 1

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Recruiting

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4